Eli Lilly news
Eli Lilly appears in 3 stories we have published between September 2026 and October 2026, mostly in our Technology and AI coverage. It is most often reported alongside Anthropic, Concordia AI and Google.
Latest development
Eli Lilly’s retatrutide reduces obstructive sleep apnea symptoms in trials
Eli Lilly’s experimental obesity drug retatrutide has demonstrated potential in reducing symptoms of obstructive sleep apnea (OSA) in recent clinical trials. The drug, which mimics multiple metabolic hormones, could offer a new treatment pathway for patients with obesity-related OSA, pending FDA approval.
26 October 2026
Covered alongside

Eli Lilly’s retatrutide reduces obstructive sleep apnea symptoms in trials
Eli Lilly’s experimental drug retatrutide, currently under review for obesity, has demonstrated potential in reducing obstructive sleep apnea symptoms…

Eli Lilly and Novo Nordisk report GLP-1 drugs may slow biological aging
Eli Lilly and Novo Nordisk report their GLP-1 weight-loss drugs may reduce biological age by 2-3 years.

Anthropic’s AI lab claims scientific discovery—biologists push back
Anthropic’s AI lab identified a DNA sequence pattern, but biologists question its validity. Meanwhile, open-weight AI models gain traction amid security concerns.
